Asterias Biotherapeutics Inc (NYSE:AST) Set to Announce Earnings on Monday

Asterias Biotherapeutics Inc (NYSE:AST) will release its earnings data after the market closes on Monday, August 14th. Analysts expect Asterias Biotherapeutics to post earnings of ($0.18) per share for the quarter.

Asterias Biotherapeutics Inc (NYSE:AST) opened at 3.25 on Friday. The company’s 50-day moving average price is $3.47 and its 200 day moving average price is $3.45. The firm’s market capitalization is $160.10 million. Asterias Biotherapeutics Inc has a 1-year low of $2.54 and a 1-year high of $5.80.

COPYRIGHT VIOLATION NOTICE: “Asterias Biotherapeutics Inc (NYSE:AST) Set to Announce Earnings on Monday” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at

A number of equities analysts recently commented on the company. HC Wainwright set a $12.00 price target on Asterias Biotherapeutics and gave the stock a “buy” rating in a research note on Thursday. Zacks Investment Research downgraded Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

What are top analysts saying about Asterias Biotherapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Asterias Biotherapeutics Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit